Dance Biopharm is a privately-held company focused on the clinical development of inhaled insulin products to treat diabetes patients worldwide.
Location: United States
Total raised: $30M
Investors 1
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.04.2019 | - | $20.5M | - |
| 18.02.2015 | - | $9.5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 29.05.2019 | How One Patient-Entrepreneur Is Impacting 100M Patients Worldwide | Healthtech Stories highlights the unique and inspiring journeys of people driven to solve healthcare’s biggest problems through technology. |
| 23.04.2019 | Dance Biopharm Holdings Completes $20.5M Financing Round | Dance Biopharm Holdings, Inc., a San Francisco, CA-based clinical stage biopharma company focused on the development of novel soft mist inhalable formulations of biologics for people living with chronic diseases, completed an approximately ... |
| 18.02.2015 | Dance Biopharm Completes $9.5M Financing | Dance Biopharm Inc., a Brisbane, CA-based biotechnology company focused on the development of inhaled insulin products to treat diabetes, completed a $9.5m convertible note and warrants financing. Participants in the financing included a sy... |
| 30.12.2014 | Maker of inhalable insulin marches on in wake of scrapped IPO | This isn’t the first time a company’s attempted an airborne diabetes med – yet there’s currently a hole in the market for such a product. Here’s why: A product called Exubera briefly hit the market around 2007 but was pulled by Pfizer barel... |
| 13.08.2013 | From inhalable insulin to vaccines: 5 diabetes companies to watch | Then there’s Pepex Biomedical, which is developing a line of all-in-one blood glucose meters that use biosensors and eliminate the need for testing strips. It’s also working on turning the technology into a cartridge that attaches to a smar... |
| - | From inhalable insulin to vaccines: 5 diabetes companies to watch | With an estimated 370 million people expected to have diabetes by 2030, the already $41 million market for diabetes management products is set to skyrocket over the next several years. Fittingly, creating devices, drugs and services aimed a... |
| - | Maker of inhalable insulin marches on in wake of scrapped IPO | It’s a drug meant for the injection-weary diabetic set: Dance Biopharm‘s developing an inhalable form of insulin, and a series accompanying electric devices to dispense the aerial hormone. It’s slated to go up against MannKind‘s Afrezza. Th... |